Charcot-Marie-Tooth Disease Market Report 2026

Charcot-Marie-Tooth Disease Market Overview

• Charcot-Marie-Tooth Disease market size has reached to $1.32 billion in 2025 • Expected to grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 20.5% • Growth Driver: Surge In Healthcare Expenditure Fueling The Growth Of The Market Due To Increasing Investment In Advanced Treatments And Services • Market Trend: Advancements In Stem Cell Therapies Driving Innovation In Neurological Disorder Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Charcot-Marie-Tooth Disease Market?

Charcot-marie-tooth (CMT) disease is a group of inherited neurological disorders that affect the peripheral nerves, which control muscles and relay sensory information from the limbs to the brain. It is characterized by progressive muscle weakness and wasting, particularly in the feet, lower legs, hands, and forearms, often accompanied by loss of sensation, foot deformities (such as high arches or hammertoes), and difficulty walking. Charcot-marie-tooth (CMT) disease is caused by gene mutations that affect the structure or function of peripheral nerves and typically begins in adolescence or early adulthood, though onset and severity can vary. The main charcot-marie-tooth disease types include CMT 1, CMT 2, CMT 3, and others. Charcot-marie-tooth disease type 1 (CMT 1) is a hereditary neuropathy caused by abnormalities in the myelin sheath surrounding peripheral nerves. It uses various drug types such as nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, tricyclic antidepressants, anticonvulsants, analgesics, and pipeline drug and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Charcot-Marie-Tooth Disease Market Growth Forecast?

The charcot-marie-tooth disease market size is expected to see exponential growth in the next few years. It will grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 20.5%. The growth in the forecast period can be attributed to gene therapy research, precision neurology, early genetic screening, rare disease funding, patient advocacy initiatives. Major trends in the forecast period include growing focus on symptom management therapies, expansion of genetic testing and diagnosis, increased use of supportive drug treatments, rising research into disease-modifying therapies, growth of multidisciplinary care models.

Global Charcot-Marie-Tooth Disease Market Segmentation

1) By Disease Type: CMT 1, CMT 2, CMT 3, Other Disease Types 2) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs, Cyclooxygenase-2 Inhibitors, Tricyclic Antidepressants, Anticonvulsants, Analgesics, Pipeline Drug 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Is The Driver Of The Charcot-Marie-Tooth Disease Market?

The surge in healthcare expenditure is anticipated to fuel the growth of the charcot-marie-tooth disease market going forward. Healthcare expenditure is the overall spending on medical services, supplies, and activities aimed at maintaining or improving health. Healthcare expenditure is rising due to the development and adoption of advanced medical technologies, which involve high costs for research, equipment, and specialized training, thereby increasing the overall spending on healthcare services. The rise in healthcare expenditure supports the demand for charcot-marie-tooth disease treatment by enabling greater investment in specialized therapies, diagnostic tools, and supportive care services, thereby improving access to comprehensive disease management. For instance in April 2025, according to the Office for National Statistics, a UK-based government agency, healthcare spending rose by 6.5% between 2023 and 2024, showing a modest increase compared to the 6.3% rise seen in 2023. Therefore, the surge in healthcare expenditure will boost the growth of the charcot-marie-tooth disease industry.

Key Players In The Global Charcot-Marie-Tooth Disease Market

Major companies operating in the charcot-marie-tooth disease market are Applied Therapeutics Inc., PTC Therapeutics Inc., Wave Life Sciences Ltd., Atalanta Therapeutics, Taysha Gene Therapies, Passage Bio Inc., Solid Biosciences Inc., Reata Pharmaceuticals, AskBio (Bayer subsidiary), Sarepta Gene Therapy, Forge Biologics, Neurogene Inc., Regenxbio Inc., Bluebird Bio Inc., GenSight Biologics SA, Rocket Pharmaceuticals Inc., Krystal Biotech Inc., Amicus Therapeutics Inc., Orchard Therapeutics plc, Anokion SA, Neurocrine Biosciences Inc., VectivBio Holding AG, Biomarin Pharmaceutical Inc., Travere Therapeutics Inc., Ascendis Pharma A/S

Global Charcot-Marie-Tooth Disease Market Trends and Insights

Major companies operating in the charcot-marie-tooth disease market are focusing on developing advanced solutions, such as mesenchymal stem cell therapies, to offer ease of isolation and expansion from various tissue sources. Mesenchymal stem cell therapies use versatile cells capable of developing into different tissue types to aid in healing and reducing inflammation in various health conditions. For instance, in March 2025, ENCell Co. Ltd., a South Korea-based biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted orphan drug designation to EN001, a mesenchymal stem cell therapy. EN001 is a mesenchymal stem cell therapy aimed at treating Charcot-Marie-Tooth (CMT) disease by improving cell survival and enhancing the release of therapeutic molecules. After administration, it focuses on repairing damaged nerves, encouraging the release of healing factors, and aiding in nerve remyelination. A phase 1 open-label, dose-escalation clinical study (NCT05333406) involving patients with type 1a CMT was conducted to assess the therapy. Using a 3+3 trial design, the study evaluated its safety, tolerability, and optimal dosing over 16 weeks, with participants in the low-dose group receiving an intravenous dose on the first day.

What Are Latest Mergers And Acquisitions In The Charcot-Marie-Tooth Disease Market?

In November 2024, the Charcot-Marie-Tooth Association (CMTA), a US-based non-profit organization, partnered with the Inherited Neuropathy Consortium (INC) to promote in-depth research across the full spectrum of charcot-marie-tooth disease variants. This collaboration helps to speed up the transition from research to clinical use, moving treatments forward and bringing optimism to those living with charcot-marie-tooth. Inherited Neuropathy Consortium (INC) is a US-based rare disease clinical research consortium.

Regional Insights

North America was the largest region in the charcot-marie-tooth disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Charcot-Marie-Tooth Disease Market?

The charcot-marie-tooth disease market consists of revenues earned by entities by providing services such as genetic testing services, physical therapy services, occupational therapy services, and orthotic fitting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The charcot-marie-tooth disease market also includes sales of custom insoles, mobility aids, electrostimulation devices, and compression garments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Charcot-Marie-Tooth Disease Market Report 2026?

The charcot-marie-tooth disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the charcot-marie-tooth disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.